Systemic Immune-Inflammation Index May Predict the Development of Contrast-Induced Nephropathy in Patients With...

Area of Science:

• Cardiology
• Nephrology
• Biomarkers

Background:

• Contrast-induced nephropathy (CIN) is a significant complication following percutaneous coronary intervention in ST-segment elevation myocardial infarction (STEMI) patients.
• Early detection of CIN is crucial for timely intervention and improved patient outcomes.
• The systemic immune-inflammation index (SII) is an emerging biomarker reflecting systemic inflammation.

Purpose of the Study:

• To evaluate the predictive capability of the systemic immune-inflammation index (SII) for detecting contrast-induced nephropathy (CIN).
• To assess the diagnostic performance of SII in patients with ST-segment elevation myocardial infarction (STEMI) undergoing contrast procedures.

Main Methods:

• A cohort of 477 STEMI patients undergoing contrast procedures was retrospectively analyzed.
• Patients were categorized into two groups based on the development of CIN.
• Receiver operating characteristic (ROC) curve analysis was employed to determine the predictive accuracy of SII.

Main Results:

• A logarithm-transformed SII cutoff of 5.91 demonstrated 73.0% sensitivity and 57.5% specificity for predicting CIN post-STEMI.
• The predictive performance of SII was comparable to high-sensitivity C-reactive protein (hs-CRP).
• SII exhibited superior predictive power compared to neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR).

Conclusions:

• The systemic immune-inflammation index (SII) serves as an independent predictor for contrast-induced nephropathy (CIN) in STEMI patients.
• SII offers a valuable, accessible biomarker for assessing CIN risk following STEMI.
• Further research may explore integrating SII into clinical risk stratification protocols for CIN.